FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 15:14:52 28/06/2024 BST | ||
| 6.41 EUR | -0.31% |
|
| Current month | +6.48% | ||
| 1 month | +6.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 6.41 | -0.31% |
| 27/06/24 | 6.43 | -5.30% |
| 26/06/24 | 6.79 | +0.30% |
| 25/06/24 | 6.77 | +3.04% |
| 24/06/24 | 6.57 | -1.35% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 03:14 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MD7WEM |
| ISIN | DE000MD7WEM6 |
| Date issued | 05/09/2022 |
| Strike | 9,865 p |
| Maturity | Unlimited |
| Parity | 4.72 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.48 € |
|---|---|
| Lowest since issue | 2.08 € |
| Spread | 0.02 € |
| Spread % | 0.32% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Certificates
- Certificat
